Research Article
Landscape of Immune Microenvironment in Epithelial Ovarian Cancer and Establishing Risk Model by Machine Learning

Shi-yi Liu, Rong-hui Zhu, Zi-tao Wang, Wei Tan, Li Zhang, Yan-qing Wang, Fang-fang Dai, Meng-qin Yuan, Ya-jing Zheng, Dong-yong Yang, Fei-yan Wang, Shu Xian, Juan He, Yu-wei Zhang, Ma-li Wu, Zhi-min Deng, Min Hu, Yan-xiang Cheng, and Ye-qiang Liu

1Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China
2Shanghai Skin Disease Clinical College of Anhui Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China
3Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200071, Shanghai, China

Correspondence should be addressed to Yan-xiang Cheng; yanxiangcheng@whu.edu.cn and Ye-qiang Liu; lyqdoctor@163.com

Received 23 February 2021; Accepted 3 August 2021; Published 27 August 2021

1.Introduction

Ovarian cancer is the second leading cause of cancer death in adult women, and the epithelial ovarian cancer (EOC) is the most common histological subtype characterized by complex adjacent anatomical structures, high-degree malignancy, and heterogeneity [1, 2]. The surgical excision and chemotherapy are effective for EOC patients, but a large fraction of EOC patients will subsequently relapse and develop to chemoresistance, which seriously shortens the patients’ clinical survival [3].

Nowadays, the immune checkpoint blockades (ICBs) have received wide attention and have emerged as efficient agents for tumor therapy. It can specifically block the immune checkpoints and retrieve the antitumor immunity [4]. Nevertheless, due to the lack of comprehensive analysis on the tumor microenvironment (TME) and EOC, there is a limited application of ICBs in EOC therapy.

The TME not only plays a critical role in carcinogenesis but also has various regulatory functions in tumor growth and metastasis [5]. It has been proposed to be valuable in diagnosis and prognosis in a wide range of tumors, but the utility on EOC
has not been investigated in detail [6]. The immune cells are a master component in TME, composed of CD8+ cytotoxic T lymphocytes (CTLs), B cells, plasma cells, macrophages, and dendritic cells (DCs) [7–9]. The class II major histocompatibility complex- (MHC-II-) restricted CTLs implicated as critical components in antitumor immunity, contributing to tumor killing [10]. And CD4+ T-helper (Th) cells are an important helper in the activation of CTLs. CTLs also can indirectly mediate tumor killing by the secretion of lymphokines such as gamma-interferon (IFN-γ), lymphotoxin [11]. In addition, DCs, a professional antigen presenting cells (APCs), are central regulators in the T-cell-mediated antitumor immunity [12]. Conversely, tumor-intrinsic immune checkpoints' ligand like programmed death ligand-1 (PD-L1) can inhibit the activation of CTLs via binding to its receptor PD-1, resulting in the tumor immune evasion [8, 13].

In this study, we intended to investigate the potential role and underlying mechanisms of TME in EOC. Immune infiltration analysis has indicated that the EOC patients with high-intensity infiltrating immune cells companied with better clinical outcomes, higher TMB, CSMD3, and MUC16 mutation. In addition, immune score was significantly related to antitumor immunity and the efficacy of ICBs in EOC. We emphasized that infiltrating dendritic cells plays a leading role in this antitumor immunity. Furthermore, we identified six DC-related prognostic genes for establishing the DC-related risk model using machine-learning Lasso regression, support vector machines (SVMs), and random forest. The well-established DC-related risk model in this study can accurately stratify patients into subgroups with different clinical survival.

2. Materials And Methods

2.1. Data. The high-throughput sequencing FPKM data (HTSeq-FPKM, \(N = 365\)) and corresponding clinicopathologic data of EOC were obtained from The Cancer Genome Atlas (TCGA, https://www.cancer.gov/). The HTSeq-FPKM data received a logarithmic conversion. In addition, Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) databases GSE63885 (GPL570) [14], GSE32062 (GPL6480) [15], GSE105437 (GPL570) [16], GSE4122 (GPL201), and GSE23554 (GPL96) [17] were also included in our study, which were retrieved and downloaded by R programming using package “ GEOquery”. GSE32062, GSE63885, and GSE23554 were measured in 260, 75, and 28 EOC patients, respectively; while the GSE105437 include 10 EOC tissues and five normal tissues; GSE4122 cohort was measured in 32 normal/benign and 32 malignant ovarian tissues.

2.2. Immune Infiltration Analysis. The “ESTIMATE” (Estimation of S'Tromal and Immune cells in MAignant Tumor tissues using Expression data) algorithm (R package “estimate”) was carried out to calculate the immune score, which refers to the infiltration level of total immune cells [18]. The populations of major types of infiltrating immune cells were evaluated through “xCell” (R package “xCell”) [19].

2.3. Somatic Mutation Analysis. The mutation MAF (minor allele frequency) file of EOC was downloaded through R package “TCGAbiolinks”. The total number of somatic mutations in each sample from TCGA was extracted through R package “maftools”. In TCGA, GRCh38 is the reference genome with a length of about 35Mb, and the formula for calculating the tumor mutation burden (TMB) is as follows [20, 21]: $\text{TMB} = \frac{\text{Sn}}{35}$ (where Sn represents the total number of somatic mutations). The R package “maftools” was also used to plotting.

2.4. Gene Set Variation Analysis. All gene sets in this study for gene set variation analysis (GSVA) were obtained from the molecular signatures database (MSigDB, https://www.gsea-msigdb.org/gsea/msigdb, Supplementary Table 1). The GSVA score of each gene set was calculated using R package “GSVA” with ssGSEA (single-sample gene set enrichment analysis) method [22, 23].

2.5. Differential Expression Analysis. EOC patients were classified into high-DC and low-DC infiltration groups based on the median level of infiltrating DCs. R package “Limma” was conducted for differential expression analysis. Absolute values of log₂ fold change (log >1) and adjusted \(p\) (adj.\(p\)) value < 0.05 were used as thresholds to identify differentially expressed genes (DEGs) [24].

2.6. Construction of Immune Molecular Risk Model. Univariable Cox survival analysis was performed to screen the potential prognostic genes (adj.\(p\) < 0.05). Feature selection was next applied by Lasso regularization (R packages “glmnet”), SVM (R packages “e1071”), and random forest (R package “randomForestSRC”, with variable relative importance > 0.4) [25]. Finally, a DC-related risk model was established by multivariable Cox analysis. The risk score was calculated as follows: risk score = CXCL9 + (0.112) + VSIG4 + (0.173) + ALOX5AP + (0.105) + TGFBI + (0.077) + UBD + (0.141) + CXCL11 + (0.120).

2.7. Statistics. All statistics were performed in R program (version 4.0.0). Student’s t-test or Wilcox test (according to the Shapiro test and Bartlett test) was applied to calculate the \(p\) value between two groups with continuous variables. Kaplan–Meier analysis was used for survival analysis, and the statistical significance was tested using the log-rank test. The correlation between two variables was assessed by the spearman correlation analysis. \(p < 0.05\) was considered statistically significant.

3. Results

3.1. High Infiltration of Immune Cells Predicts Favorable Clinical Outcomes in Epithelial Ovarian Cancer. To better understand the role of the infiltrating immune cells in EOC progression, the immune score based on the gene expression profiles was calculated using the “ESTIMATE” algorithm. As shown in results from GSE105437 and GSE4122, EOC
patients had significantly higher immune score than normal tissues (Figure 1(a) and 1(b)). This result was consistent with our previous findings that immune cells have been increasingly infiltrated into tumor microenvironment [26]. In GSE32062, the alive patients had higher immune score than the dead (Figure 1(c), \( p < 0.001 \)). In contrast, patients with high grade (Grades 3 and 4) demonstrated significantly higher immune score (Figure 1(d), \( p < 0.001 \)), while the immune score in patients with FIGO stage III and stage IV did not differ significantly (Figure 1(e)).

Regarding the most common mutation like TP53 and BRCA1/2 in EOC [27], we plotted the distribution of the immune score across other frequently mutated gene TTN, CSMD3, and MUC16 in TCGA mutation data (Figure 1(f)). Patients with high immune score had higher TMB, CSMD3, and MUC16 mutation than in wild type (Figure 1(g)–1(i), \( p < 0.05 \)). However, there were no significant correlations between immune score and mutations of TP53, TTN, BRCA1/2 (Figure 1(i)–1(k), Supplementary Figure 1).

To evaluate the potential prognostic utility of the infiltrating immune cells in EOC, the patients were initially classified into high and low groups according to the median immune score. In GSE32062 cohort, the median OS of the high and low groups were 69 and 50 months (Figure 2(a), \( p = 0.01 \)). And the immune score also was an indicator of longer progression-free survival (PFS) (Figure 2(b)). Moreover, GSE63885 also confirmed that the high immune score was correlated with better OS (Figure 2(c)). The prognostic accuracy of immune score to predict the OS in GSE32062 and GSE63885 were assessed via receiver operating characteristic (ROC) curve curves, as shown in Supplementary Figure 2, The area under the curve (AUC) value indicated that the immune score can be used to predict OS in EOC patients (Supplementary Figure 2).

### 3.2. EOC Patients with High Infiltrating Immune Cells Have an Antitumor Phenotype

The dynamic counterbalance between immuneevasion and treatment contributes to diverse immune phenotype, which is affected by lots of factors, including the infiltrating immune cells, cytokines, and immune checkpoints [28]. “xCell” algorithm was applied to quantify the different types of infiltrating immune cells. We observed high density of antigen-presenting cells in high-immune-score group, including CD8\(^+\) T cells, B cells, DCs, and macrophages M1 (Figure 2(d), all \( p < 0.001 \)). Conversely, immunosuppressive cells Tregs and macrophages M2 were more accumulated in the low group (Figure 2(e), all \( p < 0.01 \)). Besides, 16 immunostimulatory-related cytokines were overexpressed in patients with high infiltrating immune cells, which include chemokines and receptors (CXCL10, CCL11, CXCL13, CXCL9, CXCL11, CXCR3, CCL5, CCL4, CCR1, and CCL8), interferons and receptors (IL2RB, IL32, IL2RG, and IL10RA), and other cytokines (IDO1 and CSF1) (Figure 2(f), \( |\log FC| > 1, p < 0.05 \)). Moreover, the GSVA scores of innate immunity and adaptive immunity were significantly correlated with infiltrating immune cells (Figure 2(g), all \( p < 0.001 \)). We defined that EOC patients with high infiltrating immune cells tend to form an antitumor phenotype with more antitumor immune cells and immunostimulatory-related cytokines.

We next sought to investigate the correlation between infiltrating immune cells and immune checkpoints TIGIT, CD48, PDCD1 (PD-1), LAG3, CD274, HAVCR2, LAIR1, and PDCD1LG2 (PD-L2). The result elucidated that infiltrating immune cells were positively correlated with all above immune checkpoints (Figure 2(h), \( \rho > 0.6 \)). Notably, the correlation coefficients with CD48, HAVCR2, and PDCD1LG2 were more than 0.8, suggesting that EOC patients with high infiltrating immune cells may be more sensitive to ICBs therapy.

### 3.3. Dendritic Cells Shape the Immune Phenotype of EOC

To evaluate the potential prognostic utility of infiltrating immune cells in EOC, the patients were initially classified into high and low groups according to the median immune score. In GSE32062 cohort, the median OS of the high and low groups were 69 and 50 months (Figure 2(a), \( p = 0.01 \)). The immune score also was an indicator of longer progression-free survival (PFS) (Figure 2(b)). Moreover, GSE63885 also confirmed that the high immune score was correlated with better OS (Figure 2(c)). The prognostic accuracy of immune score to predict the OS in GSE32062 and GSE63885 were assessed via receiver operating characteristic (ROC) curve curves, as shown in Supplementary Figure 2. The area under the curve (AUC) value indicated that the immune score can be used to predict OS in EOC patients (Supplementary Figure 2).

We next sought to investigate the correlation between infiltrating immune cells and immune checkpoints TIGIT, CD48, PDCD1 (PD-1), LAG3, CD274, HAVCR2, LAIR1, and PDCD1LG2 (PD-L2). The result elucidated that infiltrating immune cells were positively correlated with all above immune checkpoints (Figure 2(h), \( \rho > 0.6 \)). Notably, the correlation coefficients with CD48, HAVCR2, and PDCD1LG2 were more than 0.8, suggesting that EOC patients with high infiltrating immune cells may be more sensitive to ICBs therapy.

### 3.3. Dendritic Cells Shape the Immune Phenotype of EOC

Microenvironment. The correlation between infiltrating immune cells and different types of immune cell was assessed by Spearman’s correlation analysis, and the results showed that the DCs were strongly positively correlated with immune score (Figure 3(a), \( r = 0.96, p < 0.001 \)). Meanwhile, the enrichment levels of DC-related biological processes were high in patients with high immune score (Figure 3(b)). It is worth mentioning that cytokines CCL4, CXCL9, and CXCL10, which were highly expressed in the high infiltrating immune cells group, can attract DCs (Figure 2(f)). In addition, K-M survival analysis indicated that the patients with high infiltrating DCs presented significantly better clinical survival (Figure 3(c)).

DCs are crucial participates in antigen presentation, activating MHC-I-restricted CTL responses and MHC-II-restricted CD4 + Th1 responses, both ultimately contributes to antitumor response. As shown in heatmap, almost all the MHC-I molecules (HLA-A, HLA-B, HLA-C, and B2M) and MHC-II molecules (HLA-DR, HLA-DP, HLA-DQ, HLA-DQ, HLA-DR, HLA-DR) were overexpressed in high-immune-score group (Figure 3(d)). Furthermore, high infiltrating group ranked the higher score in T helper 1 type immune response (Figure 3(e)). These suggest that DCs may play a dominant role to promoting the infiltration of immune cells into tumor microenvironment and forming an antitumor immune phenotype.

### 3.4. Construction and Validation of Dendritic Cell-Related Risk Model

As shown in volcano plot, a total of 120 genes (including 119 upregulated and 1 downregulated genes) were found to be differentially expressed in high infiltrating DC group (Figure 4(a), \( |\log FC| > 1, p < 0.05 \)). Then, 15 out of 120 DEGs were screened as the OS-related DEGs via univariate Cox analysis (Figure 4(b)). Afterward, the machine-learning Lasso regression, SVM, and random forest were employed to identify the important factors (Figure 4(c)–4(f)). Collectively, six DC-related prognostic genes CXCL9, VSIG4, ALOX5AP, TGFBI, UBD, and CXCL11 were identified to establish a risk model for EOC (Figure 4(g)). Three of them (CXCL9, UBD, and CXCL11) were protective genes with hazard ratio (HR) < 1, and others (VSIG4, ALOX5AP, and TGFBI) were risky genes (Figure 4(b)).
The DC-related risk model had been applied to TCGA cohort, which classified EOC patients into high- and low-risk groups based on median risk score (Figure 5(a)). Different OS was noticed between two subgroups (Figure 5(b), High\text{median OS} vs. Low\text{median OS}: 1162 vs. 1680 days, \( p < 0.001 \)). Moreover, the additional cohort GSE23554 (Figure 5(b), High\text{median OS} vs. Low\text{median OS}: 760 vs. 3399 days, \( p = 0.012 \)) and GSE32062 (Figure 5(c), High\text{median OS} vs. Low\text{median OS}: 50 vs. 69 months, \( p = 0.033 \)). We also confirmed that the risk score was significantly negatively correlated with infiltrating immune cells and DCs but not related to tumor purity (Figure 5(d)–5(f)).

3.5. Nomogram. To analyze the relationship between the DC-related risk model and clinical parameters, the nomogram was developed based on clinical parameters (FIGO stage and Age) integrated with the risk score. The result illustrated that the risk score we constructed was an independent predictor in EOC (Figure 6(a)). Calibration curve showed that the nomogram has a good reliability in predicting 3- and 5-year survival (Figure 6(b)).

4. Discussion

ICB therapy has been a hot topic in tumor immunotherapy and is expected to improve the outcomes of EOC patients with relapse or chemoresistance [29–31]. However, ICB's clinical application in EOC is limited seriously because the TME is complex and has not been well investigated in EOC. The work flow of this work is shown in Supplementary Figure 3; we systematically analyzed the potential role and underlying mechanisms of infiltrating lymphocytes within EOC and dug the effective predictors for EOC prognosis and ICB's therapy.
Figure 2: Continued.
Figure 2: Continued.
**Figure 2:** EOC patients with high infiltrating immune cells have an antitumor phenotype. (a–c) The high immune score was related to a better clinical survival in GSE32062 and GSE63885. Infiltration levels of (d) antitumor lymphocytes (CD8+ T cells, B cells, DCs, and macrophages M1) and (e) immunosuppressive cells (Tregs and macrophages M2) in high- and low-immune-score group. (f) Heatmap shows the expression of specific cytokines in high- and low-immune-score group. (g) Violin plots illustrate the enrichment scores of immune response biological processes evaluated by GSVA analysis between high- and low-immune-score groups. (h) Correlation between immune score and immune checkpoints, color represents the spearman’s correlation coefficient. DC: dendritic cell; GSVA: gene set variation analysis.

**Figure 3:** Continued. (a) Correlation between immune score and dendritic cells. (b) Heatmap of dendritic cell cytokine production. (c) Heatmap of dendritic cell differentiation.
In this study, we found that the immune cells were highly infiltrated into TME in carcinogenesis and predict a better clinical outcome in EOC, which are consistent with the study by Hao et al. [32], that the immune score can be used as a powerful predictive tool for both prognosis and chemotherapeutic sensitivity of EOC.

As we all know, TME phenotype was determined by a complex regulatory network involving antitumor immune responses, tumor escape, and cellular and molecular characteristics. In the current work, an antitumor phenotype with more antitumor immune cells and immunostimulatory-related cytokines was observed in high infiltrating lymphocytes group. In addition, consistent with Nishino et al. [4, 33], we also observed a strong positive correlation between infiltrating immune cells and immune checkpoints, such as CD48, HAVCR2 and PDCD1LG2, which is an important intrinsic immune surveillance escape mechanism; the PD-1, CTLA-4, BTLA, HAVCR2, and Lag3 have been proved to be the potent
immune checkpoints to mediate tumor immunosuppression [34, 35]. Among which, predominately centered on PD-L1 that overexpressed in tumor cells, leading to inhibition of CTLs’ proliferation [36]. Single-agent PD-1 blockade and PD-1/PD-L1 dual-regimen therapy both exhibit longer PFS in persistent and recurrent EOC [37]. HAVCR2 is significantly overexpressed in CD4+ and CD8+ T cells and suppress the antitumor immune responses in primary ovarian cancer, the blockade of HAVCR2 leads to sustained antitumor reactions [38]. This study suggests that EOC patients with high infiltrating immune cells may be able to achieve better efficacy in ICB’s therapy.

In addition, we observed that DCs might highly express MHC-I and MHC-II molecules, then initiating MHC-I-restricted CTLs responses and MHC-II-restricted CD4+ Th1 responses, which enables T-cell immune response [39]. All in all, DCs may play a dominant role in promoting the infiltration of immune cells into TME and forming an antitumor immune phenotype. The MHC-I/II CTLs and Th1
immune responds were activated by DCs, both can further enhance the antitumor immunity to kill the tumor cells.

Immunologicalepigeneticalterations have already become innovative and precise cancer biomarkers in urologic, brain, lung, breast, and colorectal cancers [40–42]. However, in EOC with highly heterogeneous, the traditional tumor, node, and metastasis (TNM) classification are not efficient for prognostic assessment [43]. In this study, six DC-related prognostic biomarkers (CXCL9, VSIG4, ALOX5AP, TGFBI, UBD, and CXCL11) were identified to construct risk model, which could accurately stratify the EOC patients into two subtypes with different survival outcomes, providing an informative prognostic assessment for EOC patients. We hypothesize these molecules may play important regulatory role in EOC. CXCL9 and CXCL11 are known for their tumor suppressive properties and are expressed on the DCs; CXCL9 and CXCL11 have been described to enhance antitumor immunity by activating Th1 [46]. UBD (ubiquitin D) also known as FAT10, is induced by mature DCs and contributes to antigen presentation [47]. As for risky genes, VSIG4 (V-set and Ig containing 4), a trans-membrane receptor, was expressed specifically in DCs and macrophages, which inhibited the T cells' proliferation and immune response [48, 49]. The activation of ALOX5AP (Arachidonate 5-lipoxygenase activating protein) correlates

**Figure 5:** Construction and validation of dendritic cell-related risk model. (a) The distribution of risk scores in the TCGA cohort. (b–d) K-M curves of the OS according to risk scores in (b) the training cohort and validated cohorts (c) GSE23554, (d) GSE32062. (e–g) The distribution of the (e) immune score, (f) infiltration level of DCs, and (g) tumor purity between high- and low-risk score group.
with the HER2 (human epidermal growth factor receptor 2) and promotes the growth and migration of breast cancer [50]. TGFBI (transforming growth factor beta induced) has been reported to be an oncogene in a variety of cancers including prostate, ovarian, and breast cancer [51–53]. Fico and Santa-maria-Martínez found that TGFBI induced breast cancer metastasis by regulating the TME and hypoxia [51]. The combination of interstitial TGFBI and intratumoral CD8+ T cells can be used as a predictor for PD-1/L1 blockade nivolumab [54].

5. Conclusion

In summary, our results indicate that the heavily infiltrated immune cells were positively related to a better outcome and antitumor phenotype in EOC. ICBs therapy should be considered for EOC patients with high infiltrating immune cells. In addition, we provided the mechanistic insights in this study, showing that the DCs may play an important role in the initiation of antitumor immune. Finally, we verified that the established DC-related risk model is able to accurately stratify

| Select | All | None |
|--------|-----|------|
| Points | 0   | 20   | 40   | 60   | 80   | 100  |
| Stage  |     |      |      |      |      |      |
| Age**  |     |      |      |      |      |      |
| Riskscore*** | 30 | 40 | 50 | 60 | 70 | 80 | 90 |
| Total points | 40 | 60 | 80 | 100 | 120 | 140 | 160 | 180 | 200 |

![Nomogram](image)

**Figure 6:** Nomogram. (a) Nomogram for predicting 3- and 5-year OS for EOC patients in TCGA dataset based on DC-related risk score and clinicopathological parameters (FIGO stage and age). (b) Calibration curves of nomogram in terms of agreement between predicted and actual 3- and 5-year outcomes in the TCGA cohort. The dashed line of 45° represents perfect prediction, and the actual performances of our nomogram are shown by green, red, and blue lines.
patients into subgroups with different survival outcomes. Nevertheless, further validation studies of these molecular mechanisms are still warranted in the future.

Data Availability

Previously reported sequencing data were used to support this study and are available at TCGA (https://www.cancer.gov/) and GEO (http://www.ncbi.nlm.nih.gov/geo). These prior studies and datasets are cited at relevant places within the text as references [14–16].

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Shi-yi Liu and Rong-hui Zhu contributed equally to this work.

Acknowledgments

This work has benefited from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). The authors would like to express our gratitude to these programs for its generous sharing of large amounts of data. This work was supported by the National Natural Science Foundation of China (grant no. 81860276) and the Key Special Fund Projects of National Key R&D Program (grant no. 2018YFC1003200).

Supplementary Materials

Supplementary Figure 1: the box plot shows that the BRCA1/2 mutation has no significant correlation with immune score (t-test, \( p = 0.271 \)). Supplementary Figure 2: time-dependent ROC curves in (left) GSE32062 and (right) GSE63885 indicating high accuracy of immune score in OS prediction. ROC: receiver operating characteristic; OS: overall survival. Supplementary Figure 3: the work flow of this study. Supplementary Table 1: gene sets for gene set variation analysis. (Supplementary Materials)

References

[1] S. Lheureux, M. Braunstein, and A. M. Oza, “Epithelial ovarian cancer: evolution of management in the era of precision medicine,” CA: A Cancer Journal for Clinicians, vol. 69, no. 4, pp. 280–304, 2019.
[2] S. Lheureux, C. Gourley, I. Vergote, and A. M. Oza, “Epithelial ovarian cancer,” The Lancet, vol. 393, pp. 1240–1253, Article ID 10177, 2019.
[3] S. Pignata, S. Cecere, P. Harter, and F. Heitz, “Treatment of recurrent ovarian cancer,” Annals of Oncology: Official Journal of the European Society for Medical Oncology, vol. 28, no. 8, 2017.
[4] M. Nishino, N. H. Ramaiya, H. Hatabu, and F. S. Hodi, “Monitoring immune-checkpoint blockade: response evaluation and biomarker development,” Nature Reviews Clinical Oncology, vol. 14, no. 11, pp. 655–668, 2017.
[5] D. C. Hinshaw and L. A. Shevde, “The tumor microenvironment innately modulates cancer progression,” Cancer Research, vol. 79, no. 18, pp. 4557–4566, 2019.
[6] Y. Jiang, C. Wang, and S. Zhou, “Targeting tumor microenvironment in ovarian cancer: premise and promise,” Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, vol. 1873, no. 2, Article ID 188361, 2020.
[7] X. Lei, Y. Lei, J.-K. Li et al., “Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy,” Cancer Letters, vol. 470, pp. 126–133, 2020.
[8] B. Farhood, M. Najafi, and K. Mortezaee, “CDA + cytotoxic T lymphocytes in cancer immunotherapy: a review,” Journal of Cellular Physiology, vol. 234, no. 6, pp. 8509–8521, 2019.
[9] K. F. Bol, G. Schreibelt, W. R. Gerritsen, I. J. M. de Vries, and C. G. Figdor, “Dendritic cell-based immunotherapy: state of the art and beyond,” Clinical Cancer Research, vol. 22, no. 8, pp. 1897–1906, 2016.
[10] R. Marty Pyke, W. K. Thompson, R. M. Saleem, I. Font-Burgada, M. Zanetti, and H. Carter, “Evolutionary pressure against MHC class II binding cancer mutations,” Cell, vol. 175, no. 2, pp. 416–428, 2018.
[11] T. F. Gejewski, H. Schreiber, and Y.-X. Fu, “Innate and adaptive immune cells in the tumor microenvironment,” Nature Immunology, vol. 14, no. 10, pp. 1014–1022, 2013.
[12] A. Gardner and B. Ruffell, “Dendritic cells and cancer immunity,” Trends in Immunology, vol. 37, no. 12, pp. 855–865, 2016.
[13] S. Feola, J. Chiaro, B. Martinis, and V. Cerullo, “Uncovering the tumor antigen landscape: what to know about the discovery process,” Cancers, vol. 12, no. 6, 2020.
[14] K. M. Lisowska, M. Olbryt, V. Dudaladava et al., “Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study,” Frontiers in Oncology, vol. 4, p. 6, 2014.
[15] K. Yoshiihara, T. Tsunoda, D. Shigemizu et al., “High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway,” Clinical Cancer Research, vol. 18, no. 5, pp. 1374–1385, 2012.
[16] K. Noh, L. S. Mangala, H.-D. Han et al., “Differential effects of EGFL6 on tumor versus wound angiogenesis,” Cell Reports, vol. 21, no. 10, pp. 2785–2795, 2017.
[17] D. C. Marchion, H. M. Cottrill, Y. Xiong et al., “BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival,” Clinical Cancer Research, vol. 17, no. 19, pp. 6356–6366, 2011.
[18] K. Yoshiihara, M. Shahmoradgoli, E. Martinez et al., “Inferring tumour purity and stromal and immune cell admixture from expression data,” Nature Communications, vol. 4, no. 1, pp. 2612, 2013.
[19] D. Aran, Z. Hu, and A. J. Butte, “xCell: digitally portraying the tissue cellular heterogeneity landscape,” Genome Biology, vol. 18, no. 1, p. 220, 2017.
[20] T. Jiang, J. Shi, Z. Dong et al., “Genomic landscape and its evolution and biomarker development,” The Lancet, vol. 384, no. 9949, pp. 75–84, 2014.
[21] J. Budczies, M. Allgauer, K. Litchfield et al., “Optimizing the tumor antigen landscape: what to know about the discovery process,” Cancers, vol. 12, no. 6, 2020.
[22] J. Budczies, M. Allgauer, K. Litchfield et al., “Optimizing panel-based tumor mutational burden (TMB) measurement,” Annals of Oncology, vol. 30, no. 9, pp. 1496–1506, 2019.
[23] S. Shen, G. Wang, R. Zhang et al., “Development and validation of an immune gene-set based Prognostic signature in ovarian cancer,” EBioMedicine, vol. 40, pp. 318–326, 2019.
[23] S. Zuo, M. Wei, H. Zhang et al., “A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer,” Journal of Translational Medicine, vol. 17, no. 1, p. 152, 2019.

[24] M. E. Ritchie, B. Phipson, D. Wu et al., “Limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Research, vol. 43, no. 7, Article ID e47, 2015.

[25] Y. Liu and H. Zhao, “Variable importance-weighted random forests,” Quantitative Biology, vol. 5, no. 4, pp. 338–351, 2017.

[26] D. Lambrechts, E. Wauters, B. Boeckx et al., “Phenotype molding of stromal cells in the lung tumor microenvironment,” Nature Medicine, vol. 24, no. 8, pp. 1277–1289, 2018.

[27] K. Alsop, S. Fereday, C. Meldrum et al., “BRCA mutation-positivewomen withovariancancer:areportfromtheAustralian ovariancancer study group,” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2654–2663, 2012.

[28] D. Damen, E. Vautier, F. Boeckx et al., “Phenotype of tumor-infiltrating immune cells in clear cell renal cell carcinoma (ccRCC),” Journal of Cellular Biochemistry, vol. 121, no. 3, pp. 2571–2581, 2020.

[29] K. Alsop, S. Fereday, C. Meldrum et al., “BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group,” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2654–2663, 2012.

[30] S. Liu, S. Li, Y. Wang et al., “Prognostic value of infiltrating immune cells in renal cell carcinoma,” Clinical Cancer Research, vol. 24, no. 19, pp. 4854–4863, 2018.

[31] J. H. Kim, B. K. Choi, Y. H. Kim et al., “Extracellular vesicles in breast cancer: an emerging biomarker for disease monitoring hypoxia and promotes breast cancer metastasis,” Biomark Med, vol. 14, no. 1, pp. 73–79, 2020.

[32] U. Munawara, K. Perveen, A. G. Small et al., “Human dendritic cells express the complement receptor immunoglobulin which regulates T cell responses,” JAMA Oncology, vol. 6, no. 3, pp. 375–384, 2020.

[33] G. M. Kojima, S. Genta, M. Aglietta, and G. Valabrega, “Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer?” International Journal of Molecular Sciences, vol. 17, no. 7, 2016.

[34] D. Zamarin, R. A. Burger, M. W. Sill et al., “Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study,” Journal of Clinical Oncology, vol. 38, no. 16, pp. 1814–1823, 2020.

[35] Y. Xu, H. Zhang, Y. Huang, X. Rui, and F. Zheng, “Role of TIM-3 in ovarian cancer,” Clinical and Translational Oncology, vol. 19, no. 9, pp. 1079–1083, 2017.

[36] A. Jiménez-Sánchez, D. Memon, S. Pourpe et al., “Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient,” Cell, vol. 170, no. 5, pp. 927–938, 2017.

[37] Q. Wang, B. Hu, X. Hu et al., “Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment,” Cancer Cell, vol. 32, no. 1, pp. 42–56, 2017.

[38] N. Duma, R. Santana-Davila, and J. R. Molina, “Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment,” Mayo Clinic Proceedings, vol. 94, no. 8, pp. 1623–1640, 2019.

[39] E. Becht, A. de Reyniès, A. Giraldo et al., “Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy,” Clinical Cancer Research, vol. 22, no. 16, pp. 4057–4066, 2016.

[40] M. M. Koo, R. Swann, S. McPhail et al., “Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study,” The Lancet Oncology, vol. 21, no. 1, pp. 73–79, 2020.

[41] E. Russo, A. Santoni, and G. Bernardini, “Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer,” Journal of Leukocyte Biology, vol. 108, no. 2, pp. 673–685, 2020.

[42] A. de Ming Pulido, A. Gardner, S. Hiebler et al., “TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer,” Cancer Cell, vol. 33, no. 1, pp. 60–74, 2018.

[43] R. Tokunaga, W. Zhang, M. Naseem et al., “CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy,” Cancer Treatment Reviews, vol. 63, pp. 40–47, 2018.

[44] R. Schregle, S. Mueller, D. F. Legler, J. Rossy, W. A. Krueger, and M. Greten, “FAT10 localises in dendritic cell aggregates and controls to their disassembly,” Journal of Cell Science, vol. 133, no. 14, 2020.

[45] K. H. Kim, B. K. Choi, Y. H. Kim et al., “Extra cellular stimulation of VSG4/complement receptor 1g suppresses intracellular bacterial infection by inducing autophagy,” Autophagy, vol. 12, no. 9, pp. 1647–1659, 2016.

[46] U. Munawara, K. Perveen, A. G. Small et al., “Human dendritic cells express the complement receptor immunoglobulin which regulates T cell responses,” Frontiers in Immunology, vol. 10, Article ID 2892, 2019.

[47] X. Zhou, Y. Jiang, Q. Li, Z. Huang, H. Yang, and C. Wei, “Aberrant ALOX5 activation correlates with HER2 status and mediates breast cancer biological activities through multiple mechanisms,” BioMed Research International, vol. 2020, Article ID 1703531, 2020.

[48] F. Fico and A. Santamaria-Martinez, “TGFBI modulates tumour hypoxia and promotes breast cancer metastasis,” Molecular Oncology, vol. 14, no. 12, pp. 3198–3210, 2020.

[49] Z. A. Shareef, H. Kardooni, V. Murillo-Garzón et al., “Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1,” Oncogene, vol. 37, no. 39, pp. 5305–5324, 2018.

[50] A. M. Steitz, A. Steffes, F. Finkernagel et al., “Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C,” Cell Death & Disease, vol. 11, no. 4, p. 249, 2020.

[51] N. Nakazawa, T. Yokobori, K. Kaira et al., “High stromal TGFBI in lung cancer and intratumoral CD8-positive T cells were associated with poor prognosis and therapeutic resistance to immune checkpoint inhibitors,” Annals of Surgical Oncology, vol. 27, no. 3, pp. 933–942, 2020.